Camp4 Therapeutics Corp (CAMP): Capital Expenditures
$279.0K
Year ended 2025-12-31
$129.0K
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $279.0K | -36.7% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $441.0K | -35.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $678.0K | n/a | 2025-03-27, From 2023-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $59.3K | +54.4% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $165.0K | -67.7% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $0 | -100.0% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $5.45M | -40.0% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $27.6K | +33.7% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $123.6K | n/a |
| Lipocine Inc. (LPCN) | 2024-12-31 | $90.1K | +584.2% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
Compare CAMP, CPHI, UPB, PRPH side by side · Screen every company in Pharmaceutical Preparations ↗